Medicine and Dentistry
Prostate Cancer
100%
Gemcitabine
100%
Maspin
100%
B-Cell Lymphoma
33%
Programmed Cell Death
26%
Cancer Cell
13%
Combination Therapy
13%
Western Blot
13%
Myeloid Cell
13%
Androgen
13%
Leukemia
13%
Disease
6%
Neoplasm
6%
Cancer Therapy
6%
Cell Death
6%
Short Hairpin RNA
6%
Promoter Region
6%
Real Time Polymerase Chain Reaction
6%
Flow Cytometry
6%
Lipocortin 5
6%
MTT Assay
6%
Ablation Therapy
6%
Serine Proteinase Inhibitor
6%
Biphenyl
6%
Androgen Deprivation Therapy
6%
Tetrazolium
6%
Apoptosis Assay
6%
Castration Resistant Prostate Cancer
6%
Molecularly Targeted Therapy
6%
Cytotoxicity
6%
Propidium Iodide
6%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Maspin
100%
Gemcitabine
100%
B Cell Lymphoma
33%
Androgen
20%
Western Blot
13%
Leukemia
13%
Combination Therapy
13%
Cytotoxicity
6%
Malignant Neoplasm
6%
Short Hairpin RNA
6%
Tetrazolium
6%
Flow Cytometry
6%
Propidium Iodide
6%
Lipocortin 5
6%
Apoptosis Assay
6%
Biphenyl
6%
Serine Proteinase Inhibitor
6%
Castration Resistant Prostate Cancer
6%
Disease
6%
Neoplasm
6%
Biochemistry, Genetics and Molecular Biology
Gemcitabine
100%
Maspin
100%
B Cell
33%
Cancer Cell
13%
Myeloid
13%
Western Blot
13%
Promoter Region
6%
Flow Cytometry
6%
Real-Time Polymerase Chain Reaction
6%
Propidium Iodide
6%
Apoptosis Assay
6%
Serine Protease Inhibitor
6%
Cell Death
6%
Cytotoxicity
6%
Small Hairpin RNA
6%
Annexin
6%
MTT Assay
6%